SpA non-radiografica: fase precoce di spondilite anchilosante o altro?

Size: px
Start display at page:

Download "SpA non-radiografica: fase precoce di spondilite anchilosante o altro?"

Transcription

1 Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri

2 Disclosures Consulting fees, research or institutional support and educational grants from: Abbott, Bristol Meyer Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche

3 The spondyloarthritis complex Undifferentiated SpA Juvenile SpA Psoriatic Arthritis Arthritis associated with Ulcerative colitis and Crohn s disease Ankylosing Spondylitis Reactive arthritis Acute anterior uveitis

4 Historical Look at Classification Criteria for Axial SpA Modified New York Criteria for AS Sacroiliitis (x-ray) (required) Plus 1 below: IBP/stiffness >3 months Limitation of Lumbar spine motion Limitation of chest expansion 1 van der Linden et al. Arthritis Rheum Apr;27(4):361-8.

5

6 The spondyloarthritis complex Undifferentiated SpA Juvenile SpA Psoriatic Arthritis Arthritis associated with Ulcerative colitis and Crohn s disease Ankylosing Spondylitis Reactive arthritis Acute anterior uveitis

7 Historical Look at Classification Criteria for Axial SpA Modified New York Criteria for AS Amor Classification Criteria for Spondyloarthritis Sacroiliitis (x-ray) (required) Plus 1 below: Inflammatory LBP/stiffness >3 months Limitation of Lumbar spine motion Limitation of chest expansion Scoring 6/23 points Examples: Good response to NSAIDs Expanded pain description Articular & Extra-articular manifestations Genetic Background (HLA- B27, family hx) Sacroiliitis (x-ray) 1 van der Linden et al. Arthritis Rheum Apr;27(4): Amor et al. Rev Rhum Mal Osteoartic.1990 Feb;57(2):85-9.

8

9 Historical Look at Classification Criteria for Axial SpA Modified New York Criteria for AS Amor Classification Criteria for Spondyloarthritis European Spondyloarthropathy Study Group (ESSG) Criteria Sacroiliitis (x-ray) (required) Plus 1 below: Inflammatory LBP/stiffness >3 months Limitation of Lumbar spine motion Limitation of chest expansion Scoring 6/23 points Examples: Good response to NSAIDs Expanded pain description Articular & Extra-articular manifestations Genetic Background (HLA- B27, family hx) Sacroiliitis (x-ray) IBP or Synovitis (required) Plus 1 below: Enthesitis Family hx Psoriasis, CD, or UC Preceding infection Buttock pain Sacroiliitis (x-ray) No HLA-B27 1 van der Linden et al. Arthritis Rheum Apr;27(4): Amor et al. Rev Rhum Mal Osteoartic.1990 Feb;57(2): Dougados et al, Arthritis Rheum Oct;34(10):

10

11 Historical Look at Classification Criteria for Axial SpA Modified New York Criteria for AS Amor Classification Criteria for Spondyloarthritis European Spondyloarthropathy Study Group (ESSG) Criteria Assessment of SpondyloArthritis (ASAS) Criteria for Axial Spondyloarthritis Sacroiliitis (x-ray) (required) Plus 1 below: Inflammatory LBP/stiffness >3 months Limitation of Lumbar spine motion Limitation of chest expansion Scoring 6/23 points Examples: Good response to NSAIDs Expanded pain description Articular & Extra-articular manifestations Genetic Background (HLA- B27, family hx) Sacroiliitis (x-ray) IBP or Synovitis (required) Plus 1 below: Enthesitis Family hx Psoriasis, CD, or UC Preceding infection Buttock pain Sacroiliitis (x-ray) Sacroiliitis (X-ray or MRI) Plus 1 SpA feature or HLA-B27 Plus 2 SpA features No HLA-B27 van der Linden et al. Arthritis Rheum Apr;27(4): Amor et al. Rev Rhum Mal Osteoartic.1990 Feb;57(2):85-9. Dougados et al, Arthritis Rheum Oct;34(10): Rudwaleit M et al. Ann Rheum Dis 2009;

12 Ankylosing Spondylitis Non-radiographic stage (axial undifferentiated SpA) Radiographic stage Modified New York Criteria 1984 Back pain MRI sacroiliitis Back pain Radiographic sacroiliitis Back pain Syndesmophytes Duration of symptoms (years) Rudwaleit M, et al. Arthritis Rheum. 2005;52:

13 Definition of Positive MRI-SI Joint ASAS handbook, Ann Rheum Dis 2009;68 (Suppl II) (with permission)

14 Age at First Symptoms and at First Diagnosis in Ankylosing Spondylitis Patients 14 1 Feldtkeller et al. Current Opinion in Rheum 2000;12: (with permission).

15 Ankylosing Spondylitis Non-radiographic stage (axial undifferentiated SpA) Radiographic stage Modified New York Criteria 1984 Back pain MRI sacroiliitis Back pain Radiographic sacroiliitis Back pain Syndesmophytes Duration of symptoms (years) Rudwaleit M, et al. Arthritis Rheum. 2005;52:

16 Axial spondyloarthritis Non-radiographic stage (axial undifferentiated SpA) Radiographic stage Modified New York Criteria 1984 Back pain MRI sacroiliitis Back pain Radiographic sacroiliitis Back pain Syndesmophytes Duration of symptoms (years) Rudwaleit M, et al. Arthritis Rheum. 2005;52:

17

18

19

20

21 Concept of Spondyloarthritides (SpA) Reactive arthritis Non-radiographic axial SpA Ankylosing Spondylitis Psoriatic Arthritis Arthritis with inflammatory bowel disease Undifferentiated SpA Predominantly Axial SpA Predominantly Peripheral SpA

22 Disease course of axial spondyloarthritis New Nomenclature (1) Spondyloarthritis Axial Peripheral SIJ structural damage (plain pelvic X-Rays) Yes No Ankylosing Spondylitis Axial non radiographic spondyloarthritis Axial radiographic Spondyloarthritis (1) Claudepierre P.et al. Joint Bone Spine 2012,79:534-

23 Disease course of axial spondyloarthritis Labelling of biologics in axial SpA : Ankylosing Spondylitis 2012 ongoing: [ Ankylosing Spondylitis] OR Axial non-radiographic spondyloarthritis and - SIJ inflammation at MRI OR Abnormal CRP axial spondyloarthritis with at least one of the following: - Presence of SIJ structural damage at pelvic X-Rays - Presence of SIJ inflammation at MRI or Abnormal CRP

24

25

26 Percent Female in Non-Radiographic Axial SpA Cohorts % Female sex generally >50% of nr-axspa cohort 68,2 57, ,6 47,6 1 GESPIC* Haibel ABILITY-I Kiltz ASAS Validation *GESPIC combines patients with primarily axial and primarily peripheral symptoms Rudwaleit. Arthritis Rheum. 2009:60(3) Haibel et al. Arthritis Rheum 2008;58(7): Sieper et al. ACR Tues2486A. 4 Kiltz et al. EULAR 2011 FRI Rudwaleit et al.ann Rheum Dis 2009;68:

27 Disease course of axial spondyloarthritis Structural damage in axial Spondyloarthritis * Dougados M. et al. Joint Bone Spine 2011;78:

28 Disease course of axial spondyloarthritis Cross sectional analysis of familial SpA* 86% Radiographic Sacroiliitis (%) 40% 70% <10 n = n = n = 120 Disease duration (years) *Saïd-Nahal R, Amor B, Dougados M, Breban M. Arthritis Rheum 2000;43:

29 Disease course of axial spondyloarthritis The GESPIC cohort Baseline radiographic sacroiliitis 2 year Radiographic sacroiliitis yes no Yes no % 2.6% (115) (95)

30 Disease course of axial spondyloarthritis 2 year Radiographic sacroiliitis yes no 5.7% Baseline radiographic sacroiliitis Yes no (123) (326) 4.9%

31

32 Progression from non-radiographic axial SpA to AS: Longitudinal Studies Includes² only patients age years years 1, years 1,5 % progression 8-12% 20-45% 36-59% Variable methodology and disease definitions were used in the studies reported Most studies included report mixed axial and peripheral disease at baseline No study used ASAS criteria for axial SpA Reported range represents data from different sources, study N range Sampaio-Barros et al, J Rheumatol 2010; 37: Poddubnyy et al, Ann Rheum Dis 2011; 70: Schattenkirchner et al, Clin Rheumnatol ; 6 (Suppl 2): Sany et al. Arthritis Rheum 1980;23(2): Mau et al. J Rheumatol. 1988;15: Oostveen et al, J Rheumatol 1999; 26: Bennett et al. Arthritis Rheum 2008; 58(11):

33 Hypothetical Development of Radiographic Sacroiliitis in Patients With Axial SpA Chronic back pain Radiographic Non-radiographic 100 Axial SpA (%) Time (years)

34 Disease course of axial spondyloarthritis Natural history of the disease Clinical features of Spa CDER, FDA Regulatory considerations for the potential novel indication axial spondyloarthritis. Available at: Accessed 20 February 2014.

35 Disease course of axial spondyloarthritis Natural history of the disease Clinical features of Spa Sacroiliitis on imaging CDER, FDA Regulatory considerations for the potential novel indication axial spondyloarthritis. Available at: Accessed 20 February 2014.

36 Disease course of axial spondyloarthritis Natural history of the disease Clinical features of Spa Radiographic sacroiliitis MRI sacroiliitis CDER, FDA Regulatory considerations for the potential novel indication axial spondyloarthritis. Available at: Accessed 20 February 2014.

37 Disease course of axial spondyloarthritis Natural history of the disease PROGRESSION Clinical features of Spa Radiographic sacroiliitis RESOLUTION STABILITY RESOLUTION CDER, FDA Regulatory considerations for the potential novel indication axial spondyloarthritis. Available at: Accessed 20 February 2014.

38 Disease course of axial spondyloarthritis Validity of the ASAS criteria Burden of the disease: BASFI* 43,8 BASFI (mean) 27,5 31,7 29,4 27,4 X-RAY + MRI + n = 132 X-RAY + MRI - n = 55 Imaging X-RAY - MRI + n = 99 X-RAY - MRI - CRP + n = 33 clinical X-RAY - MRI - CRP - n = 154 *Molto A Dougados M. Ann Rheum Dis 2014, jan, Epub ahead of print

39 Burden of disease in pre-radiographic axial SpA and established AS is similar 6 5 AS 5-10 yrs. (n=120) AS <5 yrs. (n=105) Pre-radiogr. AS <5 yrs. (n=196) BASDAI Pain BASFI BASMI Rudwaleit M, et al. Arthritis Rheum. 2004;50:S211.

40 ADALIMUMAB IN RHEUMATIC DISEASES Adalimumab in non-radiographic axial spondyloarthritis Efficacy (% ASAS40 response) % patients p<.001 Whole population * treatment * % patients baseline CRP * treatment p= % patients baseline sacroiliitis by MRI * treatment p= Placebo (n=94) Whole population Adalimumab (n=91) 0 n/n: 10/57 17/62 4/37 16/29 Normal Abnormal Baseline CRP 0 n/n: 7/51 17/45 7/45 16/46 Negative Positive Sacroiliitis on Baseline MRI Placebo Adalimumab Sieper J, et al. Ann Rheum Dis 2013; 72:

41

42 Pfizer 1031 study proportion of patients achieving ASAS40 response at week 12 and 24 ASAS40 response at week 12 and 24 (mitt, LOCF) 60 Double blind Open label 51, ,4 Patients (%) ,2 * 20 28,6 33,3 15,7 14,8 * 38,5 44 ETN/ETN PBO/ETN (n = 105) (n = 108) ,8 14, Weeks In this population of patients with early, active nr-axspa who had an inadequate response to 2 NSAIDs, ETN was more effective than PBO in decreasing disease activity *p<0.05; p<0.01 vs placebo. ASAS, Assessment of SpondyloArthritis international Society; ETN, etanercept; LOCF, last observation carried forward; mitt, modified intention to treat; nr-axspa, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo. Dougados M, et al. Arth Rheum 2014;66:

43 Treatment of AS and nr-axspa with Golimumab GO-RAISE Study GO-AHEAD Study In Ankylosing Spondylitis In non-radiographic axial spondyloarthritis 50 mg golimumab every four weeks vs 100 mg golimumab every four weeks vs placebo 50 mg golimumab every four weeks vs placebo Response Rate (% Patients) ASAS40 at Weeks 14 and 24 * * 49,3 44,9 15,4 15,4 43,5 Week 14 Week 24 * * 54,3 * p<0.001 PBO GLM 50 mg GLM 100 mg Abstracts with data from GO-AHEAD are presented during the scientific sessions Posters THU0218 & THU0238 Abstract AB0757 CHMP positive opinion for nr-axspa indication received May 2015 n= Inman R et al. A&R 2008; 58:

44 Take home messages

45 CONCLUSIONS Non-radiographic/Non-imaging axial spondyloarthritis DOES EXIST The natural history of axial spondyloarthritis requires further investigations Non-radiographic/Non-imaging axial spondyloarthritis deserves to have access to all the therapies available for radiographic axial spondyloarthritis

46 Grazie per l attenzione

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion

More information

What is Axial Spondyloarthritis?

What is Axial Spondyloarthritis? Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy

More information

Gender differences in effectiveness of treatment in rheumatic diseases

Gender differences in effectiveness of treatment in rheumatic diseases Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical

More information

Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation

Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging? Results from the DESIR cohort of patients with recent onset axial spondyloarthritis Ho Yin Chung

More information

Concept of Spondyloarthritis (SpA)

Concept of Spondyloarthritis (SpA) Concept of Spondyloarthritis (SpA) Spondyloarthritis: Characteristic Parameters Used for Diagnosis I Symptoms Inflammatory back pain Imaging Lab ESR/CRP Patient s history Good response to NSAIDs Spondyloarthritis-Characteristic

More information

Chapter 2. Overview of ankylosing spondylitis

Chapter 2. Overview of ankylosing spondylitis Chapter 2 Overview of ankylosing spondylitis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises AS, reactive arthritis, arthritis/spondylitis associated with

More information

Dr Tracey Kain. Associate Professor Ed Gane

Dr Tracey Kain. Associate Professor Ed Gane Associate Professor Ed Gane New Zealand Liver Transplant Unit Auckland Dr Tracey Kain Consultant Rheumatologist Grace Orthopaedic Centre Tauranga Hospital Tauranga 7:00-7:55 Abbvie Breakfast Session 1.

More information

Imaging of axial spondyloarthritis including ankylosing spondylitis

Imaging of axial spondyloarthritis including ankylosing spondylitis Imaging of axial spondyloarthritis including ankylosing spondylitis ACR 2012 Prof. Dr. med. J. Braun Rheumazentrum Ruhrgebiet, Herne Ruhr-Universität Bochum Germany Modified New York Criteria 1984 for

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs

More information

Radiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally

Radiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally RHEUMATOLOGY Rheumatology 2017;56:811 817 doi:10.1093/rheumatology/kew496 Advance Access publication 4 February 2017 Original article Radiographic sacroiliitis develops predictably over time in a cohort

More information

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Ghosh and Ruderman Arthritis Research & Therapy (2017) 19:286 DOI 10.1186/s13075-017-1493-8 REVIEW Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Nilasha Ghosh and Eric M.

More information

Axial Spondyloarthritis: Issues & Controversies

Axial Spondyloarthritis: Issues & Controversies Axial Spondyloarthritis: Issues & Controversies Atul Deodhar, MD Professor of Medicine Oregon Health & Science University Portland, OR WRA 2018 Annual Meeting, Leavenworth, WA. 16 th September, 2018 Disclosures:

More information

ARTHRITIS ADVISORY COMMITTEE MEETING

ARTHRITIS ADVISORY COMMITTEE MEETING ARTHRITIS ADVISORY COMMITTEE MEETING July 23, 2013 sbla 125057/323: adalimumab for the treatment of Active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation by elevated

More information

Overview of axial spondyloarthritis

Overview of axial spondyloarthritis Chapter 2 Overview of axial spondyloarthritis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises ankylosing spondylitis (AS), reactive arthritis, arthritis/spondylitis

More information

Golimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic

Golimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe and 100mg/mL solution for injection in pre-filled pen (Simponi ) SMC No. (1124/16) Merck Sharp & Dohme Limited 8 January 2016 The

More information

Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients

Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients E. Koumakis, L. Gossec, M. Elhai, V. Burki, A. Durnez, I. Fabreguet, M. Meyer, J. Payet, F. Roure, S. Paternotte, M. Dougados

More information

37 year old male with several year history of back pain

37 year old male with several year history of back pain 37 year old male with several year history of back pain Inflammatory Low Back Pain Clues onset before the age of 40 years insidious onset, chronic (>3 months) pain morning stiffness for longer than 30

More information

ARTHRITIS ADVISORY COMMITTEE MEETING

ARTHRITIS ADVISORY COMMITTEE MEETING ARTHRITIS ADVISORY COMMITTEE MEETING July 23, 2013 sbla 125160/215: Cimzia (certolizumab) for the treatment of active axial spondyloarthritis, including patients with ankylosing spondylitis Disclaimer

More information

adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)

adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Assessment of Inflammatory Back Pain: New Concepts in Diagnosis

Assessment of Inflammatory Back Pain: New Concepts in Diagnosis Assessment of Inflammatory Back Pain: New Concepts in Diagnosis March 2 nd, 2018 Spine Therapy Network Interprofessional Synposium Sheraton Toronto Airport Hotel, Toronto, CANADA Laura Passalent PT, BScPT,

More information

NIH Public Access Author Manuscript Curr Opin Rheumatol. Author manuscript; available in PMC 2011 January 20.

NIH Public Access Author Manuscript Curr Opin Rheumatol. Author manuscript; available in PMC 2011 January 20. NIH Public Access Author Manuscript Published in final edited form as: Curr Opin Rheumatol. 2010 September ; 22(5): 603 607. doi:10.1097/bor.0b013e32833c7255. Early axial spondyloarthritis Robert A Colbert

More information

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study EXTENDED REPORT Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study Walter P Maksymowych, 1 Maxime Dougados, 2 Désirée van

More information

New developments in the diagnosis and treatment of axial spondyloarthritis

New developments in the diagnosis and treatment of axial spondyloarthritis Review: Clinical Trial Outcomes New developments in the diagnosis and treatment of axial spondyloarthritis Clin. Invest. (2013) 3(2), 153 171 Spondyloarthritis (SpA) is an umbrella term for a group of

More information

Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line

Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited

More information

Assessing the Signs, Symptoms, and Clinical Manifestations of Axial SpA

Assessing the Signs, Symptoms, and Clinical Manifestations of Axial SpA Physiotherapist Module 3 Assessing the Signs, Symptoms, and Clinical Manifestations of Axial SpA Enhance your patient examination skills Claire Harris, Senior Physiotherapist, London North West Healthcare

More information

Assessing the Signs, Symptoms, and Clinical Manifestations of Axial SpA

Assessing the Signs, Symptoms, and Clinical Manifestations of Axial SpA This resource was organised and funded by AbbVie. It has been developed in collaboration with Claire Harris, Susan Gurden, Dr Jane Martindale, Claire Jeffries and NASS. For UK healthcare professionals

More information

Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis

Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis DOI 10.1007/s11926-012-0274-2 SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR) Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis Salih Ozgocmen & Muhammad Asim Khan

More information

Multiple Technology Appraisal (MTA)

Multiple Technology Appraisal (MTA) National Institute for Health and Care Excellence Multiple Technology Appraisal (MTA) TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing

More information

Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA)

Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA) www.printo.it/pediatric-rheumatology/gb/intro Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA) Version of 2016 1. WHAT IS JUVENILE SPONDYLOARTHRITIS/ENTHESITIS- RELATED ARTHRITIS (SpA-ERA)

More information

Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis

Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 6, June 2016, pp 1415 1421 DOI 10.1002/art.39542 VC 2016, American College of Rheumatology Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis

More information

Rheumatology Subcommittee of PTAC Meeting held 7 October (minutes for web publishing)

Rheumatology Subcommittee of PTAC Meeting held 7 October (minutes for web publishing) Rheumatology Subcommittee of PTAC Meeting held 7 October 2014 (minutes for web publishing) Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

10/28/2013. Disclosure. Ustekinumab. IL-12, IL-23 and Ustekinumab. IL-23 in Facet Joints in Patients with AS

10/28/2013. Disclosure. Ustekinumab. IL-12, IL-23 and Ustekinumab. IL-23 in Facet Joints in Patients with AS for the Treatment of Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study (TOPAS) Disclosure The study was supported by an unrestricted research

More information

2004 Health Press Ltd.

2004 Health Press Ltd. ... Ankylosing spondylitis Maxime Dougados MD Professor of Rheumatology Hôpital Cochin René Descartes University Paris, France Désirée van der Heijde MD PhD Professor of Rheumatology University Hospital

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 23 April 2009 Doc. Ref. CPMP/EWP/4891/03 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL

More information

ESPONDILOARTROPATÍAS. Dr. Julio Ramírez García

ESPONDILOARTROPATÍAS. Dr. Julio Ramírez García ESPONDILOARTROPATÍAS Dr. Julio Ramírez García Bloque 1: Caracterización de los pacientes con SpA axial ABSTRACT NUMBER: 1509 Similarities and Differences between Non-Radiographic and Radiographic Axial

More information

A mong the inflammatory rheumatic diseases

A mong the inflammatory rheumatic diseases 659 REVIEW Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care J Sieper, M Rudwaleit... An earlier diagnosis of ankylosing spondylitis

More information

SPARTAN NEWS. Greetings!

SPARTAN NEWS. Greetings! Volume 3 Issue 1 SPARTAN NEWS Greetings! I am looking forward to seeing you at our Annual Meeting in Cambridge, MA and encourage you to register for the meeting as soon as possible if you haven't had the

More information

Golimumab: a novel anti-tumor necrosis factor

Golimumab: a novel anti-tumor necrosis factor Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher

More information

ARD Online First, published on October 11, 2005 as /ard

ARD Online First, published on October 11, 2005 as /ard ARD Online First, published on October 11, 2005 as 10.1136/ard.2005.044206 Combining information obtained from MRI and conventional radiographs in order to detect sacroiliitis in patients with recent-onset

More information

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort Ortolan et al. Arthritis Research & Therapy (2018) 20:218 https://doi.org/10.1186/s13075-018-1705-x RESEARCH ARTICLE Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data

More information

Spondyloarthritis: Practice. New Concepts in. Epidemiology and Clinical

Spondyloarthritis: Practice. New Concepts in. Epidemiology and Clinical New Concepts in Spondyloarthritis: Epidemiology and Clinical Practice Atul Deodhar MD Professor of Medicine Oregon Health & Science University Portland, OR Northwest Rheumatism Society, Seattle, April

More information

T he spondyloarthritides (SpA) comprise five subtypes:

T he spondyloarthritides (SpA) comprise five subtypes: 1305 EXTENDED REPORT Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept M Rudwaleit*, X

More information

Anja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2

Anja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2 Weiß et al. Arthritis Research & Therapy 2014, 16:R35 RESEARCH ARTICLE Open Access Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long

More information

Introduction. Natural Progression of AS. Sacroiliac Joint. Clinical Features and Assessment of Ankylosing Spondylitis

Introduction. Natural Progression of AS. Sacroiliac Joint. Clinical Features and Assessment of Ankylosing Spondylitis Clinical Features and Assessment of Ankylosing Spondylitis Dr. YIM, Cheuk Wan Specialist in Rheumatology United Christian Hospital Introduction Ankylo=fusion Spondylitis=inflammation of spine Affect 0.1-0.5%

More information

Imaging and intervention of sacroiliac joint. Dr Ryan Lee Ka Lok Associate Consultant Prince of Wales Hospital

Imaging and intervention of sacroiliac joint. Dr Ryan Lee Ka Lok Associate Consultant Prince of Wales Hospital Imaging and intervention of sacroiliac joint Dr Ryan Lee Ka Lok Associate Consultant Prince of Wales Hospital Introduction 15%-25% of low back pain is related to sacroiliac joint (SIJ) pain SIJ pain is

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29572 holds various files of this Leiden University dissertation. Author: Berg, Rosaline van den Title: Spondyloarthritis : recognition, imaging, treatment

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue

More information

I J Sørensen,15 R Valle-Oñate,16 U Weber,17 J Wei,18 J Sieper,1,19

I J Sørensen,15 R Valle-Oñate,16 U Weber,17 J Wei,18 J Sieper,1,19 See Editorial, pg 1 Additional data (supplementary table) are published online only. To view these fi les please visit the journal online (http://ard.bmj. com). 1 Department of Medicine, Charité University

More information

Paediatric rheumatology

Paediatric rheumatology Paediatric rheumatology Low frequency of axial involvement in southern Italian Caucasian children with HLA-B27 positive juvenile onset undifferentiated spondyloarthritis I. Olivieri 1, M.S. Cutro 1, S.

More information

ABSTRACT Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis

ABSTRACT Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis 1 Rheumatology, Med Klinik I, Charité, Campus Benjamin Franklin, Berlin, Germany; 2 Leiden University Medical Center, Leiden, The Netherlands; 3 Maastricht University Medical Center, Maastricht, The Netherlands;

More information

CLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH

CLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH CLOSER LOOK AT SpA Dr. Mohamed Bedaiwi Consultant Rheumatologist Rheumatology Unit - KKUH Closer look at SpA I. Categories II. SIGN & SYMPTOMS III. X-RAY IV. MRI V. MANAGMENT Spondyloarthritis (SpA)

More information

www.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high

More information

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort To cite: Abawi O, van den Berg R, van der Heijde D, et al. Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. RMD Open 2017;3:e000389.

More information

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; 4. Key words MRI, sacroiliitis, ankylosing spondylitis, axial spondyloarthritis.

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; 4. Key words MRI, sacroiliitis, ankylosing spondylitis, axial spondyloarthritis. Gadolinium contrast-enhanced MRI sequence does not have an incremental value in the assessment of sacroiliitis in patients with early inflammatory back pain by using MRI in combination with pelvic radiographs:

More information

Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care

Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Joy Schechtman D.O. Professor Midwestern University 64C-1876207 Disclosures None 3 64C-1876207

More information

BRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1

BRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1 ARTHRITIS & RHEUMATOLOGY Vol. 67, No. 9, September 2015, pp 2369 2375 DOI 10.1002/art.39225 VC 2015, American College of Rheumatology BRIEF REPORT Clinical Course Over Two Years in Patients With Early

More information

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis Márta Péntek Márta Péntek Systematic review and analysis

More information

2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material

2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis Online supplementary material 1. Introduction A systematic literature review (SLR) was performed to inform the

More information

EULAR UCB, Inc. All rights reserved. For unsolicited request only.

EULAR UCB, Inc. All rights reserved. For unsolicited request only. 1 EULAR 213 2 CZP in AxSpA Effects of certolizumab pegol (CZP) on the signs and symptoms of AxSpA at week 24 (RAPID-AxSpA) 3 RAPID-AxSpA: Ongoing 24-week trial in adult patients with active AxSpA according

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

The Challenge of Diagnosis and Classification in Early Ankylosing Spondylitis

The Challenge of Diagnosis and Classification in Early Ankylosing Spondylitis ARTHRITIS & RHEUMATISM Vol. 52, No. 4, April 2005, pp 1000 1008 DOI 10.1002/art.20990 2005, American College of Rheumatology COMMENTARY The Challenge of Diagnosis and Classification in Early Ankylosing

More information

Concept of Spondyloarthritis (SpA)

Concept of Spondyloarthritis (SpA) Concept of Spondyloarthritis (SpA) Undifferentiated SpA Juvenile SpA Ankylosing Spondylitis Psoriatic Arthritis Arthritis associated with Ulcerative Colitis/ Crohn s Disease Reactive Arthritis Acute anterior

More information

Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies

Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies Jose Aliling 1 and Lawrence H Brent 1* Einstein Medical Center, USA * Corresponding Author: Lawrence H Brent, Einstein Medical

More information

van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/ /s

van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/ /s van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/10.1186/s13075-018-1556-5 RESEARCH ARTICLE Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis

More information

Netherlands, Atrium Medical Center, Heerlen, the Netherlands. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy

Netherlands, Atrium Medical Center, Heerlen, the Netherlands. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy DR. SOFIA RAMIRO (Orcid ID : 0000-0002-8899-9087) Article type : Full Length Is it useful to repeat MRI of the sacroiliac joints after three months or one year in the diagnostic process of patients with

More information

ORIGINAL ARTICLE. Ho Yin Chung & Chak Sing Lau & Ka Pik Wu & Woon Sing Wong & Mo Yin MOK

ORIGINAL ARTICLE. Ho Yin Chung & Chak Sing Lau & Ka Pik Wu & Woon Sing Wong & Mo Yin MOK Clin Rheumatol (2011) 30:947 953 DOI 10.1007/s10067-011-1693-6 ORIGINAL ARTICLE Comparison of performance of the Assessment of Spondyloarthritis International Society, the European Spondyloarthropathy

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda) RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic

More information

5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments

5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures

More information

Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts

Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts presented at the 2012 American College of Rheumatology meeting

More information

AWMSG SECRETARIAT ASSESSMENT REPORT. Certolizumab pegol (Cimzia ) 200 mg solution for injection. Reference number: 1211 FULL SUBMISSION

AWMSG SECRETARIAT ASSESSMENT REPORT. Certolizumab pegol (Cimzia ) 200 mg solution for injection. Reference number: 1211 FULL SUBMISSION AWMSG SECRETARIAT ASSESSMENT REPORT Certolizumab pegol (Cimzia ) 200 mg solution for injection Reference number: 1211 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics and Toxicology

More information

SPONDYLOARTHRITIS: PATHOGENESIS, CLINICAL MANIFESTATIONS, DIAGNOSIS, AND MANAGEMENT

SPONDYLOARTHRITIS: PATHOGENESIS, CLINICAL MANIFESTATIONS, DIAGNOSIS, AND MANAGEMENT SPONDYLOARTHRITIS: PATHOGENESIS, CLINICAL MANIFESTATIONS, DIAGNOSIS, AND MANAGEMENT *Pilar S. del Río-Martínez Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain *Correspondence to psdelrio@yahoo.es

More information

The Complex/Challenging Spine Patient Steve Wisniewski, M.D. Department of PM&R

The Complex/Challenging Spine Patient Steve Wisniewski, M.D. Department of PM&R The Complex/Challenging Spine Patient Steve Wisniewski, M.D. Department of PM&R 2011 MFMER slide-1 Disclosures None 2011 MFMER slide-2 Learning Objectives Review indications for obtaining imaging studies

More information

PREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE PREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Introduction: Inflammatory arthritis is the most common extraintestinal manifestation in patients with inflammatory

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

C. Assess clinical response after the first three months of treatment.

C. Assess clinical response after the first three months of treatment. Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit

More information

Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis

Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis 12 October 2017 EMA/CPMP/EWP/4891/03 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Draft agreed by

More information

6/6/2017. Spondyloarthritis and Osteopathic Primary Care: Facts and Challenges. Progression of Ankylosing Spondylitis Classic Disease

6/6/2017. Spondyloarthritis and Osteopathic Primary Care: Facts and Challenges. Progression of Ankylosing Spondylitis Classic Disease 1 Outline Talk 1 Introduction of spondyloarthritis (SpA) Clinical case challenge The problem of low back pain (LBP) in primary care and in osteopathic primary care Talk 2 What is SpA today? How many people

More information

Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis

Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis , pp.319 325 Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis Mitulescu TC* ***, Popescu C* **, Naie A*, Predeţeanu D* **, Popescu V***, Alexandrescu C***, Voinea LM*

More information

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort de Winter et al. Arthritis Research & Therapy (2018) 20:38 https://doi.org/10.1186/s13075-018-1535-x RESEARCH ARTICLE Open Access Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis:

More information

Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Followup

Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Followup Journal of Crohn's and Colitis, 2016, 166 175 doi:10.1093/ecco-jcc/jjv195 Advance Access publication October 28, 2015 Original Article Original Article Classifying Back Pain and Peripheral Joint Complaints

More information

Review Developments in the scientific and clinical understanding of the

Review Developments in the scientific and clinical understanding of the Review Developments in the scientific and clinical understanding of the spondyloarthritides Joachim Sieper Department of Rheumatology, Campus Benjamin Franklin, Charité, Hindenburgdamm 30, 12200 Berlin,

More information

Perspective CME CME. Therapeutics for the treatment of spondyloarthritis: what, when and whom. Éric Toussirot*1,2 & Fabrice Michel1

Perspective CME CME. Therapeutics for the treatment of spondyloarthritis: what, when and whom. Éric Toussirot*1,2 & Fabrice Michel1 Therapeutics for the treatment of spondyloarthritis: what, when and whom The therapeutic management of ankylosing spondylitis (AS) and spondyloarthritis includes AIDs and biological therapies (TNFa antagonists),

More information

Ruben Burgos-Vargas *

Ruben Burgos-Vargas * Burgos-Vargas Pediatric Rheumatology 2012, 10:14 REVIEW Open Access The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis

More information

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including

More information

Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data

Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data Arthritis Care & Research Vol. 67, No. 11, November 2015, pp 1571 1577 DOI 10.1002/acr.22614 VC 2015, American College of Rheumatology ORIGINAL ARTICLE Hierarchy of Impairment of Spinal Mobility Measures

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)

More information

SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect

SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect PRODUCT INFORMATION NAME OF THE MEDICINE Golimumab (rmc) CAS Registry Number: 476181-74-5 DESCRIPTION

More information

Update - Imaging of the Spondyloarthropathies. Spondyloarthropathies. Spondyloarthropathies

Update - Imaging of the Spondyloarthropathies. Spondyloarthropathies. Spondyloarthropathies Update - Imaging of the Spondyloarthropathies Donald J. Flemming, M.D. Dept of Radiology Penn State Hershey Medical Center Spondyloarthropathies Family of inflammatory arthritides of synovium and entheses

More information

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry Arthritis Care & Research Vol. 70, No. 11, November 2018, pp 1661 1670 DOI 10.1002/acr.23534 2018, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College

More information

Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients

Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients J. Payet, L. Gossec, S. Paternotte, V. Burki, A. Durnez, M. Elhai, I. Fabreguet, E. Koumakis,

More information

Citation for published version (APA): Paramarta, J. E. (2014). Spondyloarthritis: From disease phenotypes to novel treatments

Citation for published version (APA): Paramarta, J. E. (2014). Spondyloarthritis: From disease phenotypes to novel treatments UvA-DARE (Digital Academic Repository) Spondyloarthritis: From disease phenotypes to novel treatments Paramarta, Jacky Link to publication Citation for published version (APA): Paramarta, J. E. (2014).

More information

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic

More information

2014 Update on the CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis

2014 Update on the CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis 2014 Update on the CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis Dr. Sherry Rohekar May 24, 2014 Learning Objectives Learn about proposed principles of the management of

More information

Strengthening our knowledge in Spondylarthritides: Focusing on Ankylosing Spondylitis and Psoriatic Arthritis

Strengthening our knowledge in Spondylarthritides: Focusing on Ankylosing Spondylitis and Psoriatic Arthritis Department of Pathophysiology Metical School National and Kapodestrian University of Athens Strengthening our knowledge in Spondylarthritides: Focusing on Ankylosing Spondylitis and Psoriatic Arthritis

More information

ABSTRACT Objectives. To investigate the effectiveness

ABSTRACT Objectives. To investigate the effectiveness Clinical and Experimental Rheumatology 2011; 29: 80-84. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve-month observational study in a group of patients treated

More information

Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878.

Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878. Chapter 12 References Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878. Amor B, Dougados M, Listrat V, et al. Are classification criteria for spondylarthropathy

More information

Dougados et al. Arthritis Research & Therapy 2014, 16:481 Page 2 of 13 (Continued from previous page)

Dougados et al. Arthritis Research & Therapy 2014, 16:481 Page 2 of 13  (Continued from previous page) Dougados et al. Arthritis Research & Therapy 2014, 16:481 RESEARCH ARTICLE Open Access Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results

More information

Muhammad Haroon 1* Oliver FitzGerald 4. , Muddassar Ahmad 1, Muhammad Nouman Baig 2, Olivia Mason 3, John Rice 2 and

Muhammad Haroon 1* Oliver FitzGerald 4. , Muddassar Ahmad 1, Muhammad Nouman Baig 2, Olivia Mason 3, John Rice 2 and Haroon et al. Arthritis Research & Therapy (2018) 20:73 https://doi.org/10.1186/s13075-018-1565-4 RESEARCH ARTICLE Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids

More information